LIGAND PHARMACEUTICALS INCORPORATED
Asset & Liabilities Breakdown
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
FY2014
FY2013
FY2012
FY2011
FY2010
Asset Breakdown FY2020
Total Assets: $1.36B
Liabilities Breakdown FY2020
Total Liabilities: $652.8M
Asset Breakdown
Total Assets: $1.36B
| Line Item | Value | % of Total |
|---|---|---|
| Cash & Equivalents | $47.6M | 3.5% |
| Accounts Receivable | $56.8M | 4.2% |
| Inventory | $26.5M | 1.9% |
| Property, Plant & Equipment | $13.2M | 1.0% |
| Goodwill | $189.7M | 13.9% |
| Intangible Assets | $595.3M | 43.7% |
| Other Assets | $433.1M | 31.8% |
Liabilities Breakdown
Total Liabilities: $652.8M
| Line Item | Value | % of Total |
|---|---|---|
| Accounts Payable | $3.8M | 0.6% |
| Long-Term Debt | $0 | 0.0% |
| Other Liabilities | $649.0M | 99.4% |